DRG Epidemiology's coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of neuroendocrine tumor for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
DRG Epidemiology's neuroendocrine tumor forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuroendocrine tumor over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Note: Coverage may vary by country
- Neuroendocrine Tumor - Epidemiology - Epidemiology Dashboard
- Neuroendocrine Tumors Epidemiology Dashboard
Author(s): Swarali Tadwalkar
Swarali Tadwalkar, M.P.H., is a senior epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.